ArticleAlzheimer's research & therapy2013
Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies.
Article in Alzheimer's research & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2.International psychogeriatrics · 2024Trial
- Trial
- Predicting clinical progression trajectories of early Alzheimer's disease patients.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Application of a Novel Endpoint Staging Framework: Proof of Concept in the AMBAR Study.Journal of Alzheimer's disease : JAD · 2024Article
- Gut-brain axis and neurodegeneration: mechanisms and therapeutic potentials.Frontiers in neuroscience · 2024Review
- The Association between Metformin Use and Risk of Developing Severe Dementia among AD Patients with Type 2 Diabetes.Biomedicines · 2023Article
- Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease.Neurology and therapy · 2021Article
- Effects of Alzheimer's and Vascular Pathologies on Structural Connectivity in Early- and Late-Onset Alzheimer's Disease.Frontiers in neuroscience · 2021Article
- Pathways of Prevention: A Scoping Review of Dietary and Exercise Interventions for Neurocognition.Brain plasticity (Amsterdam, Netherlands) · 2019Article
- Quantification of Galantamine inTurkish journal of pharmaceutical sciences · 2019Article
- Robust Identification of Alzheimer's Disease subtypes based on cortical atrophy patterns.Scientific reports · 2017Article
- Early diagnosis of mild cognitive impairment and mild dementia through basic and instrumental activities of daily living: Development of a new evaluation tool.PLoS medicine · 2017Article
- Trajectories of dementia-related cognitive decline in a large mental health records derived patient cohort.PloS one · 2017Article
- Observational
- Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.Alzheimer's research & therapy · 2016Observational
- Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab.Alzheimer's & dementia (New York, N. Y.) · 2015Article
- Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review.Alzheimer's research & therapy · 2015Article
- Real-world evaluation of compliance and preference in Alzheimer's disease treatment.Clinical interventions in aging · 2015Article
- Solitary living in Alzheimer's disease over 3 years: association between cognitive and functional impairment and community-based services.Clinical interventions in aging · 2014Article
- Longitudinal Sensitivity of Alzheimer's Disease Severity Staging.American journal of Alzheimer's disease and other dementiasArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionKnowledge of longitudinal progression in mild Alzheimer's disease (AD) is required for the evaluation of disease-modifying therapies. Our aim was to observe the effects of long-term cholinesterase inhibitor (ChEI) therapy in mild AD patients in a routine clinical setting.
methodsThis was a prospective, open-label, non-randomized, multicenter study of ChEI treatment (donepezil, rivastigmine or galantamine) conducted during clinical practice. The 734 mild AD patients (Mini-Mental State Examination (MMSE) score 20 to 26) were assessed at baseline and then semi-annually over three years. Outcome measures included the MMSE, Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), Clinician's Interview-Based Impression of Change (CIBIC) and Instrumental Activities of Daily Living (IADL) scale.
resultsAfter three years of ChEI therapy, 31% (MMSE) and 33% (ADAS-cog) of the patients showed improved/unchanged cognitive ability, 33% showed improved/unchanged global performance and 14% showed improved/unchanged IADL capacity. Higher mean dose of ChEI and lower educational level were both predictors of more positive longitudinal cognitive and functional outcomes. Older participants and those with a better IADL score at baseline exhibited a slower rate of cognitive decline, whereas younger participants and those with higher cognitive status showed more preserved IADL ability over time. Gender and apolipoprotein E (APOE) genotype showed inconsistent results. Prediction models using the abovementioned scales are presented.
conclusionsIn naturalistic mild AD patients, a marked deterioration in IADL compared with cognitive and global long-term outcomes was observed, indicating the importance of functional assessments during the early stages of the disease. The participants' time on ChEI treatment before inclusion in studies of new therapies might affect their rate of decline and thus the comparisons of changes in scores between various studies. An increased understanding of expected disease progression in different domains and potential predictors of disease progression is essential for assessment of future therapies in AD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.